(Q36374193)

13 August 2017

1 reference

title

Controversies in atrial fibrillation (English)

1 reference

13 August 2017

0 references

2

Lionel H Opie

1 reference

13 August 2017

1

Stanley Nattel

1 reference

PubMed ID

16427496

13 August 2017

language of work or name

English

0 references

publication date

1 January 2006

1 reference

13 August 2017

1 reference

13 August 2017

367

1 reference

13 August 2017

9506

1 reference

13 August 2017

262-272

1 reference

Comparing the guidelines: anticoagulation therapy to optimize stroke prevention in patients with atrial fibrillation

13 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

From delirium cordis to atrial fibrillation: historical development of a disease concept

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

New ideas about atrial fibrillation 50 years on.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

Pulmonary vein isolation for paroxysmal and persistent atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

The relationship of human atrial cellular electrophysiology to clinical function and ultrastructure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

The efficacy of the Cox/maze procedure combined with mitral valve surgery: a matched control study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

Pharmacological approach for the prevention of atrial fibrillation after cardiovascular surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

New approaches to atrial fibrillation management: a critical review of a rapidly evolving field.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

Rhythm or rate control in atrial fibrillation--Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

A comparison of rate control and rhythm control in patients with atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

Rate vs rhythm control in patients with atrial fibrillation: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

Catheter ablation for atrial fibrillation in congestive heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

Amiodarone versus sotalol for atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

Novel targets for cardiac antiarrhythmic drug development.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

Therapeutic implications of atrial fibrillation mechanisms: can mechanistic insights be used to improve AF management?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

Ablation therapy for atrial fibrillation (AF): past, present and future

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

Effects of sinus rhythm restoration in patients with persistent atrial fibrillation: a clinical, echocardiographic and hormonal study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

Effect of rate and rhythm control on left ventricular function and cardiac dimensions in patients with persistent atrial fibrillation: results from the RAte Control versus Electrical Cardioversion for Persistent Atrial Fibrillation (RACE) study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: approaches to control rate in atrial fibrillation.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

Relation between achieved heart rate and outcomes in patients with atrial fibrillation (from the Atrial Fibrillation Follow-up Investigation of Rhythm Management [AFFIRM] Study).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

Ionic remodeling underlying action potential changes in a canine model of atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

Cellular mechanisms of atrial contractile dysfunction caused by sustained atrial tachycardia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

Intracellular calcium changes and tachycardia-induced contractile dysfunction in canine atrial myocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

Electrical and contractile remodeling during the first days of atrial fibrillation go hand in hand

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

Consequences of atrial electrical remodeling for the anti-arrhythmic action of class IC and class III drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

Does flecainide regain its antiarrhythmic activity after electrical cardioversion of persistent atrial fibrillation?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

Ionic targets for drug therapy and atrial fibrillation-induced electrical remodeling: insights from a mathematical model

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

Time course of recovery of left atrial mechanical dysfunction after cardioversion of spontaneous atrial fibrillation with the implantable atrial defibrillator

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

Effect of the implantable atrial defibrillator on the natural history of atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

Spontaneous episodes of atrial fibrillation after implantation of the Metrix Atrioverter: observations on treated and nontreated episodes. Metrix Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

Clinical evaluation of a policy of early repeated internal cardioversion for recurrence of atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

Early cardioversion of atrial fibrillation facilitated by transesophageal echocardiography: short-term safety and impact on maintenance of sinus rhythm at 1 year

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

Rate control in atrial fibrillation: choice of treatment and assessment of efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

An update on electrical cardioversion of atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

Management of atrial fibrillation: review of the evidence for the role of pharmacologic therapy, electrical cardioversion, and echocardiography

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

Experimental evidence for proarrhythmic mechanisms of antiarrhythmic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

Management of newly detected atrial fibrillation: a clinical practice guideline from the American Academy of Family Physicians and the American College of Physicians

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

Electrical reversion of cardiac arrhythmias

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

Atrial stunning: basics and clinical considerations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

Pulmonary vein denervation enhances long-term benefit after circumferential ablation for paroxysmal atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

Response of atrial fibrillation to pulmonary vein antrum isolation is directly related to resumption and delay of pulmonary vein conduction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

Pulmonary vein isolation as an end point for left atrial circumferential ablation of atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

Stroke severity in atrial fibrillation. The Framingham Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

Haemostatic and haemodynamic abnormalities associated with left atrial thrombosis in non-rheumatic atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

Risk factors for thromboembolism during aspirin therapy in patients with atrial fibrillation: The stroke prevention in atrial fibrillation study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

Validation of Clinical Classification Schemes for Predicting Stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

Economic factors associated with antithrombotic treatments for stroke prevention in patients with atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

Stroke prevention in atrial fibrillation: physicians' attitudes to anticoagulation in older people

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

Anticoagulant-related bleeding in older persons with atrial fibrillation: physicians' fears often unfounded

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

Thromboembolic complications in atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

Characteristics and prognosis of lone atrial fibrillation. 30-year follow-up in the Framingham Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

Asymptomatic or "silent" atrial fibrillation: frequency in untreated patients and patients receiving azimilide

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

Impairment of left atrial function predicts post-operative atrial fibrillation after coronary artery bypass graft surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

Stroke after coronary artery bypass: incidence, predictors, and clinical outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

Usefulness of atrial fibrillation as a predictor of stroke after isolated coronary artery bypass grafting

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

The efficacy of anticoagulant therapy in preventing embolism related to D.C. electrical conversion of atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

Risk for clinical thromboembolism associated with conversion to sinus rhythm in patients with atrial fibrillation lasting less than 48 hours

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Co

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

Clinical trials update from the European Society of Cardiology meeting 2005: CARE-HF extension study, ESSENTIAL, CIBIS-III, S-ICD, ISSUE-2, STRIDE-2, SOFA, IMAGINE, PREAMI, SIRIUS-II and ACTIVE

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

Warfarin for atrial fibrillation: the end of an era?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

Effects of antiarrhythmic drugs on fibrillation in the remodeled atrium: insights into the mechanism of the superior efficacy of amiodarone

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

N-3 Fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968037-9

7 January 2021

10.1016/S0140-6736(06)68037-9

Identifiers

DOI

1 reference

13 August 2017

1 reference

PubMed ID

16427496